Crossmark

Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma

Crossref DOI link: https://doi.org/10.1038/s41598-025-23185-7

Published Online: 2025-11-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamada, Daisaku

Kobayashi, Shogo

Takahashi, Hidenori

Iwagami, Yoshifumi

Akita, Hirofumi

Asukai, Kei

Shimizu, Junzo

Yamada, Terumasa

Tanemura, Masahiro

Yokoyama, Shigekazu

Tsujie, Masanori

Asaoka, Tadafumi

Takeda, Yutaka

Morimoto, Osakuni

Tomokuni, Akira

Doki, Yuichiro

Eguchi, Hidetoshi
Clinical Trials ^BETA

Clinical trials referenced in this document:

umin000021484 at UMIN Japan

Documents that mention this clinical trial

Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenocarcinoma
https://doi.org/10.1038/s41598-025-23185-7
License Information

Text and Data Mining valid from 2025-11-12

Version of Record valid from 2025-11-12
More Information

Article History

Received: 3 April 2025

Accepted: 6 October 2025

First Online: 12 November 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below